INVERSAGO-PHARMA
15.3.2022 13:07:06 CET | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.
This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year.
“We are pleased that the clinical trials for INV-202, our first-in-class, peripheral CB1 inhibitor, are moving ahead swiftly,” said Dr. François Ravenelle, Chief Executive Officer of Inversago. “This pharmacokinetic and safety study will also measure a number of well accepted biomarkers of metabolic disorders. Together, these results are expected to act as a guide for the next phase of INV-202’s development.”
Inversago is planning to launch its first Phase 2 study in patients with Diabetic Nephropathy (DN) shortly after results are available. DN involves a chronic loss of kidney function in people with type-1 and type-2 diabetes who also often present obesity. This patient profile allows for the objective measurement of primary endpoints specific to DN and secondary endpoints relevant to metabolic diseases at large. The company believes that this choice of indication provides the optimal proof of concept to demonstrate the therapeutic breadth of opportunity available to INV-202 and the rest of the Inversago pipeline.
Peripheral CB1 inverse agonists, such as Inversago’s lead INV-202 molecule, have demonstrated efficacy in addressing multiple pathways involved in renal injury. Aside effects on albuminuria in pre-clinical models, CB1 inverse agonists have shown clinical improvements in lipids, weight loss and glucose. Each of these effects have separately demonstrated reno-protective characteristics.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005525/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sytel Reply Named Zuora’s 2025 EMEA RSI Partner of the Year Enabling Value-Based Monetization for AI24.3.2026 13:21:00 CET | Press release
Sytel Reply, the Reply Group company specialized in subscription management, billing transformation and revenue management platforms, has been recognized by Zuora as its 2025 EMEA RSI Partner of the Year for its expertise in Zuora implementation and strategic consulting in monetization across the EMEA region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324359888/en/ By combining deep platform expertise, revenue model design capabilities and advanced AI solutions, Sytel Reply and Revise Reply position themselves as strategic partners for organizations seeking to evolve their business models and transform AI adoption into tangible and sustainable economic value. The recognition highlights more than a decade of experience on the Zuora platform and a dedicated center of excellence comprising certified specialists in subscription management, revenue recognition, billing optimization and financial analytics. Sytel Reply supp
Klarna and Elliott Deepen Partnership With $2bn Facility Supporting $17bn of US Financing Expansion24.3.2026 13:07:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today doubled its existing forward-flow and whole-loan sale agreement with investment funds managed by Elliott Investment Management. The facility size doubles to $2bn and the term extends by one year to three years, enabling Klarna to facilitate up to $17bn-worth of US Financing loans during the remaining life of the program. "Klarna's US Financing is growing fast because it gives Americans something the credit card industry never has: real choice, clear terms, and no surprises. This partnership sets the foundation for us to meet the accelerating demands of our American consumers." — Niclas Neglen, Chief Financial Officer, Klarna The upsizing reflects the strong performance of the program since the two companies first announced their partnership in November 2025. In Q4 2025, Klarna's US Financing GMV grew significantly, and the expanded facility gives Klarna further capacity to support the accelerated demand. Under the ag
NetApp and Elastio Announce Partnership to Deliver Defense-in-Depth Ransomware Resilience24.3.2026 13:00:00 CET | Press release
Robust cyber resilience requires both perimeter defenses and built-in security at the storage layer NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Elastio are helping enterprises enhance their cyber resilience with a layered defense that extends from production storage into recovery data. Security teams must be ready to address threats at every layer of their technology stack, including ransomware that moved quietly through production before it was caught that now lives inside snapshots and backups. Advanced ransomware is engineered to evade prevention tools, moving quietly through production, staying below detection thresholds, reaching backup data before any alert is triggered. "As we migrated our infrastructure, ensuring we had the right level of backup security and assurance was non-negotiable,” Marc Crudgington, VP IT Infrastructure and CISO, Crane WW Logistics. “Elastio provided continuous inspection of our backups from day one - giving us confidence in
NetApp and Commvault Advance Cyber Resilience with Strategic Alliance24.3.2026 13:00:00 CET | Press release
Joint unified cyber resilience solution delivers data security and rapid recovery across hybrid environments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Commvault (NASDAQ: CVLT), a leader in unified resilience at enterprise scale, today announced a strategic alliance to deliver a powerful, integrated solution for enterprise data protection and cyber resilience. The unified solution enables resilience, security, and rapid recovery for customers across on-premises and cloud environments, giving organizations confidence that their data is always available, immutable, and recoverable. “This alliance reinforces NetApp and Commvault’s leadership in the rapidly evolving cyber resilience and data protection market,” said Dallas Olson, Chief Commercial Officer at NetApp. “Together we’re helping customers make their infrastructure intelligent and secure so they have the confidence that their data is always available, protected, and recoverable—no matter where it live
SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0”24.3.2026 13:00:00 CET | Press release
Pioneering the “Performance Medicine” category for full-scale entry into the longevity market — targeting a global market projected to reach $2 trillion by 2035 SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced “SBC Wellness 2.0,” a new wellness and longevity platform that combines aesthetic healthcare, preventative care, and data-driven health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323000188/en/ SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0” The initiative positions SBC Medical to participate in the fast-growing longevity market, which is projected to reach approximately $800 billion in 2025* and expand to approximately $2 trillion by 2035, with a compound annual growth rate exceeding 10% from 2026 to 2035. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom